Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Very strong margins and returns
About
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company...
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITDA,
Target Price
The average target price of CPRX is 32 and suggests 32% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
